

If a conflict arises between a Clinical Payment and Coding Policy and any plan document under which a member is entitled to Covered Services, the plan document will govern. If a conflict arises between a CPCP and any provider contract pursuant to which a provider participates in and/or provides Covered Services to eligible member(s) and/or plans, the provider contract will govern. "Plan documents" include, but are not limited to, Certificates of Health Care Benefits, benefit booklets, Summary Plan Descriptions, and other coverage documents. Blue Cross and Blue Shield of TX may use reasonable discretion interpreting and applying this policy to services being delivered in a particular case. Blue Cross and Blue Shield of TX has full and final discretionary authority for their interpretation and application to the extent provided under any applicable plan documents.

Providers are responsible for submission of accurate documentation of services performed. Providers are expected to submit claims for services rendered using valid code combinations from Health Insurance Portability and Accountability Act approved code sets. Claims should be coded appropriately according to industry standard coding guidelines including, but not limited to: Uniform Billing Editor, American Medical Association, Current Procedural Terminology, CPT® Assistant, Healthcare Common Procedure Coding System, ICD-10 CM and PCS, National Drug Codes, Diagnosis Related Group guidelines, Centers for Medicare and Medicaid Services National Correct Coding Initiative Policy Manual, CCI table edits and other CMS guidelines.

Claims are subject to the code edit protocols for services/procedures billed. Claim submissions are subject to claim review including but not limited to, any terms of benefit coverage, provider contract language, medical policies, clinical payment and coding policies as well as coding software logic. Upon request, the provider is urged to submit any additional documentation.

Epithelial Cell Cytology in Breast Cancer Risk Assessment

Policy Number: CPCPLAB024

Version 1.0

Approval Date: Sept. 13, 2024

Plan Effective Date: Jan. 1, 2025 (Blue Cross and Blue Shield of Texas Only)

Description

The plan has implemented certain lab management reimbursement criteria. Not all requirements apply to each product. Providers are urged to review Plan documents for eligible coverage for services rendered.

Reimbursement Information:

Cytologic analysis of epithelial cells to assess breast cancer risk and manage patients at high risk of breast cancer **is not reimbursable**.

Procedure Codes

The following is not an all-encompassing code list. The inclusion of a code does not guarantee it is a covered service or eligible for reimbursement.

Codes
88108, 88112, 88172, 88173, 88177

References:

- ASBS. (2016). *Consensus Guideline on Concordance Assessment of Image-Guided Breast Biopsies and Management of Borderline or High-Risk Lesions*.
<https://www.breastsurgeons.org/docs/statements/Consensus-Guideline-on-Concordance-Assessment-of-Image-Guided-Breast-Biopsies.pdf>
- ASBS. (2019). *Screening Mammography*.
<https://www.breastsurgeons.org/docs/statements/Position-Statement-on-Screening-Mammography.pdf>
- Chatterton, R. T., Heinz, R. E., Fought, A. J., Ivancic, D., Shappell, C., Allu, S., Gapstur, S., Scholtens, D. M., Gann, P. H., & Khan, S. A. (2016). Nipple Aspirate Fluid Hormone Concentrations and Breast Cancer Risk. *Horm Cancer*, 7(2), 127-136.
<https://doi.org/10.1007/s12672-016-0252-7>
- FDA. (2017). *Nipple Aspirate Test Is No Substitute for Mammogram*. Center for Devices and Radiological Health. <https://www.fda.gov/consumers/consumer-updates/nipple-aspirate-test-no-substitute-mammogram>
- Golshan, M. (2022). Nipple discharge - UpToDate. In W. Chen (Ed.), *UpToDate*.
<https://www.uptodate.com/contents/nipple-discharge>
- Hornberger, J., Chen, S. C., Li, Q., Kakad, P., & Quay, S. C. (2015). Proliferative epithelial disease identified in nipple aspirate fluid and risk of developing breast cancer: a systematic review. *Curr Med Res Opin*, 31(2), 253-262.
<https://doi.org/10.1185/03007995.2014.988209>

Joe, B., & Esserman, L. (2023, May 3). *Breast biopsy*. <https://www.uptodate.com/contents/breast-biopsy>

Kamali, G. H., & Kamali, S. (2022). The Role of Ductal Lavage Cytology in the Diagnosis of Breast Cancer. *Archives of Iranian Medicine (AIM)*, 25(11).

Kooistra, B. W., Wauters, C., van de Ven, S., & Strobbe, L. (2009). The diagnostic value of nipple discharge cytology in 618 consecutive patients. *Eur J Surg Oncol*, 35(6), 573-577. <https://doi.org/10.1016/j.ejso.2008.09.009>

Moelans, C. B., Patuleia, S. I. S., van Gils, C. H., van der Wall, E., & van Diest, P. J. (2019). Application of Nipple Aspirate Fluid miRNA Profiles for Early Breast Cancer Detection and Management. *Int J Mol Sci*, 20(22). <https://doi.org/10.3390/ijms20225814>

Moy, L., Heller, S. L., Bailey, L., D'Orsi, C., DiFlorio, R. M., Green, E. D., Holbrook, A. I., Lee, S. J., Lourenco, A. P., Mainiero, M. B., Sepulveda, K. A., Slanetz, P. J., Trikha, S., Yepes, M. M., & Newell, M. S. (2017). ACR Appropriateness Criteria® Palpable Breast Masses. *J Am Coll Radiol*, 14(5s), S203-s224. <https://doi.org/10.1016/j.jacr.2017.02.033>

NCCN. (2023, June 19). *NCCN Clinical Practice Guidelines in Oncology; Breast Cancer Screening and Diagnosis V1.2023*. National Comprehensive Cancer Network. https://www.nccn.org/professionals/physician_gls/pdf/breast-screening.pdf

Sanford, M. F., Slanetz, P. J., Lewin, A. A., Baskies, A. M., Bozzuto, L., Branton, S. A., Hayward, J. H., Le-Petross, H. T., Newell, M. S., Scheel, J. R., Sharpe, R. E., Jr., Ulaner, G. A., Weinstein, S. P., & Moy, L. (2022). ACR Appropriateness Criteria® Evaluation of Nipple Discharge: 2022 Update. *J Am Coll Radiol*, 19(11s), S304-s318. <https://doi.org/10.1016/j.jacr.2022.09.020>

Shaheed, S. U., Tait, C., Kyriacou, K., Linforth, R., Salhab, M., & Sutton, C. (2018). Evaluation of nipple aspirate fluid as a diagnostic tool for early detection of breast cancer. *Clin Proteomics*, 15, 3. <https://doi.org/10.1186/s12014-017-9179-4>

Policy Update History:

Approval Date	Effective Date; Summary of Changes
09/13/2024	01/01/2025: New policy.